Solvonis Therapeutics Provides Update on SVN-SDN-014 Preclinical Program
Why we think this is neutral
This RNS announcement provides an update on the preclinical development of Solvonis Therapeutics' SVN-SDN-014 program, which is targeting trauma-related mental health conditions including PTSD. The announcement outlines the progress made in the program, including the completion of candidate synthesis, and the next steps in the development plan. As this is a clinical trial update and does not contain any financial or operational performance information, the sentiment is assessed as neutral.
Key Points
- Solvonis Therapeutics has completed the synthesis of development candidates for its SVN-SDN-014 program, a novel series of serotonin, dopamine, and noradrenaline modulators targeting trauma-related mental health conditions
- The program aims to develop a new class of medicines for PTSD, which affects an estimated 20 million people across the United States, United Kingdom, and key European markets
- The compounds in development are designed to enhance pro-social behaviour and improve the safety profile compared to existing investigational treatments for PTSD
- Solvonis is progressing the program toward formal lead selection and IND-enabling studies
Summary
Solvonis Therapeutics plc (LSE: SVNS) has provided an update on the progress of its preclinical program, SVN-SDN-014, a novel series of serotonin (SERT), dopamine (DAT), and noradrenaline (NET) modulators in development for trauma-related mental health conditions, including Post-Traumatic Stress Disorder (PTSD). The company has now completed the synthesis of development candidates, marking the third of seven stages in the SVN-SDN-014 translational development plan. The remaining stages include in-vitro screening, preclinical animal testing, and lead candidate selection, which is expected by the end of Q3 2025.